Get 50% OFF This Monsoon!

Advertisement
AdvertisementAdvertisement
logo

Alivus Life Sciences

ALIVUS
Small Cap
(%) 1D
no_data

No Data Available

1D1W1M3M6M1YMAX

Investor Sentiment

50%50%
Bullish
Bearish
Advertisement
AdvertisementAdvertisement

Alivus Life Sciences Share price and Fundamental Analysis

View All Details
View All Details
The company was incorporated as Zorg Laboratories Private Limited', a private limited company under the Companies Act, 1956 on 23 June 2011 at Pune and was granted the certificate of incorporation by the Registrar of Companies, Maharashtra at Pune ('RoC'). Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited pursuant to the Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' pursuant to a special resolution passed by the shareholders of the Company on 25 July 2018 and a fresh certificate of incorporation dated 10 August 2018 was issued by the RoC. A shareholders' resolution was passed on 13 August 2018 to convert the Company from a private limited company to a public limited company and a fresh certificate of incorporation dated 28 August 2018 was issued by the RoC. The Company is a wholly owned Subsidiary of Glenmark Pharmaceuticals Limited. The Company acquired API division of Glenmark Pharmaceuticals Limited (the parent company) on 01 January 2019.
Company Incorporation2011
ChairmanGlenn Saldanha
Head QuartersNA
Previous NameGlenmark Life Sciences Ltd

Key Metrics

Market Cap (Cr)
11,555
PE Ratio
23.32
Industry P/E
33.01
PEG Ratio
2.16
ROE
17.24%
ROCE
22.84%
ROA
14.53%
Total Debt (Cr)
56.61
Debt to Equity
0.02
Dividend Yield
0.53%
EPS
40.4
Book Value & P/B
229.65 x 4.1
Face Value
2
Outstanding Shares(Cr)
12.27
Current Ratio
5.03
EV to Sales
4.81

Included In

+More

Stock Returns

1 Week-2.95%
1 Month-7.37%
6 Months+6.42%
1 Year-10.54%
3 Years+114.19%
5 Years+25.81%
no_data

No Stocks

Smart Score

1.8
icn

Unlock Smart Score

See Detailed Analysis & Insights

icn

Unlock Insights

See Detailed Analysis & Insights

Technicals

Returns Calculator

If you would have invested
In 5 years the current value would be
NaNCRNaNCR( %)

Research Report

No Research Report

View Other Reports >

Corporate Action

Board-Meetings
Board-Meetings
Dividends
Bonus
Splits
Right-issues
AGM-EGM
Bulk-Deal
Block-Deal

Financials

Half Yearly Statement

PARTICULARS

Total Revenue

Total Expenses

Operating Expense

Operating Profit

Interest

Depreciation & Amortization

Profit Before Tax

Tax

Profit after tax

Adj EPS in Rs - Basic

Adj EPS in Rs - Diluted

Profit and Loss Statement

Credit Rating
Director Report
Chairman Report
Auditor Report
Mar 25

Promoters : 74.99%

FIIs : 6.57%

DIIs : 5.19%

Public : 13.25%

Promoter
FII/FPI
DII
Public
Promoter Pledge stands at 0.0% of holding in March 2025 Qtr
DII Shareholding Increased by 0.33% to 5.19% in March 2025 Qtr
FII Shareholding Decreased by 0.17% to 6.57% in March 2025 Qtr

Top Shareholders

View all Share Holders

Key Ratios

Profitability
Valuation
Liquidity

ROE

Avg ROE (3 Yrs) : NaN%

ROCE

Avg ROCE (3 Yrs) : NaN%

ROA

Avg ROA (3 Yrs) : NaN%

NPM

Avg NPM (3 Yrs) : NaN%

Dividend History

Alivus Life Sciences Competitors

Sector
Industry

Company Name

MCap(TTM)

PE(TTM)

P/B(TTM)

ROE(TTM)

D/E

Current Ratio(TTM)

5 Year FactSheet

Profitability
Profitability
Growth Ratios
Valuation Ratios
Cashflow Ratios
Debt and Liquidity
Efficiency Ratios

Documents

Annual Reports
Con-Call

News

Alivus Life Sciences Management and History

Company Management

icn

Unlock Management Data

See Detailed Analysis & Insights

Company History

The company was incorporated as Zorg Laboratories Private Limited', a private limited company under the Companies Act, 1956 on 23 June 2011 at Pune and was granted the certificate of incorporation by the Registrar of Companies, Maharashtra at Pune ('RoC'). Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited pursuant to the Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' pursuant to a special resolution passed by the shareholders of the Company on 25 July 2018 and a fresh certificate of incorporation dated 10 August 2018 was issued by the RoC. A shareholders' resolution was passed on 13 August 2018 to convert the Company from a private limited company to a public limited company and a fresh certificate of incorporation dated 28 August 2018 was issued by the RoC. The Company is a wholly owned Subsidiary of Glenmark Pharmaceuticals Limited. The Company acquired API division of Glenmark Pharmaceuticals Limited (the parent company) on 01 January 2019.

The company is primarily engaged in the business of development,manufacture and marketing of Active Pharmaceutical Ingredients(APIs). The company's R&D facilities are located at Mahape,Ankleshwar and Dahej and manufacturing facilities are located at Ankleshwar,Dahej,Mohol and Kurkumbh.

During the year 2018-19, the company allotted 4,50,090 Equity Shares of Rs. 10/- each on the conversion of loan given to Director. During the year, 15,00,000 equity shares of the face value of Rs. 10 each fully paid-up issued to Glenmark Pharmaceuticals Limited (Parent Company) pursuant to the Preferential Allotment.

Subsequent to the quarter ended 30 June 2021, the company has completed the IPO of 21,022,222 equity shares comprising a fresh issue of 14,722,222 equity shares and offer for sale of 6,300,000 equity shares of face value of Rs 2 each at premium of Rs 718 per share aggregating to Rs 15,136 million. Pursuant to the IPO, the equity shares of the Company are listed on BSE Limited and National Stock Exchange of India Limited with effect from 06 August 2021.

The Gross Debt comprising of Outstanding Purchase Consideration payable to the Parent Company was Rs 8,008.3 million as on 09 July 2021.The Company has repaid the whole of this remaining outstanding purchase consideration from the proceeds of the Fresh Issue pursuant to the IPO.

Alivus Life Sciences Share Price

Alivus Life Sciences share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.

Alivus Life Sciences Market Cap

Market capitalization of Alivus Life Sciences indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Alivus Life Sciences is valued compared to its competitors.

Alivus Life Sciences PE Ratio

Alivus Life Sciences PE ratio helps investors understand what is the market value of each stock compared to Alivus Life Sciences 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.

Alivus Life Sciences PEG Ratio

The PEG ratio of Alivus Life Sciences evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.

Alivus Life Sciences ROE (Return on Equity)

Return on Equity (ROE) measures how effectively Alivus Life Sciences generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.

Alivus Life Sciences ROCE (Return on Capital Employed)

Return on Capital Employed (ROCE) evaluates the profitability of Alivus Life Sciences in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.

Alivus Life Sciences Total Debt

Total debt of Alivus Life Sciences shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.

Alivus Life Sciences Debt to Equity Ratio

The Debt-to-Equity (DE) ratio of Alivus Life Sciences compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.

Alivus Life Sciences CAGR (Compound Annual Growth Rate)

CAGR shows the consistent growth rate of Alivus Life Sciences over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.

Alivus Life Sciences Technical Analysis

Technical analysis of Alivus Life Sciences helps investors get an insight into when they can enter or exit the stock. Key components of Alivus Life Sciences Technical Analysis include:

Support Levels (S1, S2, S3)

There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.

Resistance Levels (R1, R2, R3)

There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Alivus Life Sciences shares often struggle to rise above due to selling pressure.

Alivus Life Sciences Dividends

Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Alivus Life Sciences ’s financial health and profitability.

Alivus Life Sciences Bonus Shares

Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.

Alivus Life Sciences Stock Split

Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.

Alivus Life Sciences Financials

The financials of Alivus Life Sciences provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.

Alivus Life Sciences Profit and Loss Statements

The profit and loss statement of Alivus Life Sciences highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Alivus Life Sciences .

Alivus Life Sciences Balance Sheet

The balance sheet presents a snapshot of Alivus Life Sciences ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.

Alivus Life Sciences Cashflow Statements

Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.